Articles tagged with Chemotherapy
Researchers have developed a new technique called iontophoresis that delivers high concentrations of chemotherapy directly to tumors, reducing the risk of damaging healthy tissue. This technology has the potential to improve treatment outcomes for cancer patients by allowing for more potent anti-cancer drugs to be used.
A new study published in Journal of Clinical Oncology finds that ultrasound can help surgeons decide whether to remove only a few or all underarm lymph nodes from breast cancer patients who have received chemotherapy, reducing the risk of complications and saving healthcare costs.
Researchers discovered a new way to shrink ovarian cancer tumors by inhibiting abnormal angiogenesis. Using a naturally occurring protein inhibitor called 3TSR, the approach improved chemotherapy drug delivery and resulted in significant tumor regression and survival.
A study found that multiplexed genetic screening for EGFR and ALK gene rearrangements followed by molecularly-guided treatment is cost-effective compared to standard chemotherapy. The approach offers better outcomes in terms of quality-adjusted life years gained and life-years, making it a valuable option for patients with NSCLC.
A recent study by OIST researchers used chemogenetic inhibition to suppress neuronal activity in zebra finches, showing that the arcopallium region controls song composition but not order or timing. This precise technique provides a detailed understanding of how unique neurons coordinate vocalization.
Researchers found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The study demonstrates the use of nanotechnology to repurpose existing chemotherapy drugs as effective agents against chemoresistant cancer stem cells.
Researchers found that endothelial cells, the cells lining blood vessels, play a more active role in tumor growth than previously thought. A combination therapy involving anti-Angiopoietin-2 and metronomic chemotherapy showed promising results in reducing metastatic growth and improving survival rates in mice.
A study found that entecavir significantly reduced the incidence of hepatitis B virus (HBV)-related hepatitis and HBV reactivation among patients receiving rituximab-based chemotherapy. The rates were lower in the entecavir group compared to the lamivudine group, with significant reductions in HBV-related complications.
Research shows adding chemotherapy drug carboplatin or blood vessel-targeting drug bevacizumab to standard preoperative chemotherapy increases pathologic complete response rates for women with basal-like triple-negative breast cancer. The drugs also showed benefits in certain gene signatures associated with aggressive disease.
Researchers identified increased risk of jaw bone disease in patients taking osteoporosis medications, anticancer drugs, or glucocorticoids. Prevention strategies include good oral hygiene, antibiotics, and surgical treatments to protect at-risk individuals.
Researchers developed a fast and accurate method for screening cancer drugs using gold nanoparticles, allowing for rapid profiling of various anti-cancer drugs and their mechanisms. This new sensor system uses three-channel detection to identify specific cell death mechanisms, enabling the determination of drug mechanisms in minutes.
Researchers found that trastuzumab benefits HER2-positive breast cancer patients do not depend on the number of tumor-infiltrating lymphocytes (S-TILs) in their tumors. The study, which measured S-TILs at diagnosis in over 1,000 patients, showed improved recurrence-free survival when chemotherapy alone was used.
Researchers identified two subtypes of breast cancer, Epi-Basal and Epi-Luminal B, which differ in their epigenetic patterns. The subtype Epi-Luminal B is associated with reduced survival rates and requires adjuvant chemotherapy.
Researchers identified two compounds that inhibit mitochondrial energy enzyme MDH2, blocking cardiac damage caused by doxorubicin and reducing heart failure risk. The findings suggest that these compounds could improve cancer treatment outcomes while minimizing cardiac toxicity.
A team of researchers has discovered a way to make triple-negative breast cancer cells susceptible to chemotherapy by inhibiting the HIF protein network. The study found that HIF inhibitors can decrease tumor size and prevent relapse in mice, offering new hope for treatment-resistant patients.
Market-access agreements for anti-cancer drugs lack transparency, leading to higher prices for patients in small and low-income countries. The financial arrangements between pharmaceutical manufacturers and health systems are kept confidential, making it difficult for these countries to negotiate lower prices.
Researchers have discovered novel combinations of targeted therapies and chemotherapy regimens that improve survival outcomes for patients with historically poor-prognosis leukemia. These findings, presented at the American Society of Hematology Annual Meeting, offer new hope for elderly and aggressive genetic mutation patients.
A late-stage clinical trial demonstrated that brentuximab vedotin can improve progression-free survival and overall survival in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant. The study showed a 20% improvement in progression-free survival rate and high response rates among patients.
Researchers have developed a new technique to wrap chemotherapy drugs in fatty covers called liposomes, reducing heart damage and improving cardiac function. The study found that the group receiving Myocet had better diastolic and systolic function compared to conventional doxorubicin, with less fibrosis development.
Researchers have developed a novel approach to drug screening that could more precisely tailor chemotherapy to a patient's individual blood cancer type. By correcting for the matrix effect, Shin and Mooney believe their approach could identify a subset of drugs that will be more likely to be effective against chronic myeloid leukemias.
A recent study published in the New England Journal of Medicine found that crizotinib significantly improves symptoms and delays cancer growth in patients with ALK-positive non-small cell lung cancer. The trial involved 343 previously untreated patients, showing promising results without unexpected side effects.
Researchers found that cancer stem cells regrow and respond to chemotherapy-induced damage by releasing prostaglandin E2, leading to therapy resistance. Blocking PGE2 could potentially enhance therapeutic response, offering a promising new treatment for bladder cancer.
Researchers at UNC School of Medicine found that the chemotherapy drug topotecan suppresses a gene essential for normal brain function, leading to neurological side effects like memory loss and confusion. The effects are reversible upon removal of the drug, suggesting a potential link to autism.
Breast cancer patients undergoing chemotherapy and immediate breast reconstruction are at risk of thrombotic complications, which can delay or modify reconstructive plans. In some cases, these complications require anticoagulation therapy and may necessitate additional surgeries.
Researchers at the University of Adelaide have discovered that cancer cells with chromosomal instability are vulnerable to mild metabolic disruption, making them a potential target for new therapy. The study's findings suggest that targeting these unstable cells could lead to more effective treatments with fewer side effects.
Scientists from Queen Mary University of London have developed a new therapy for advanced bladder cancer, showing significant tumor shrinkage in patients. The treatment, MPDL3280A, has been given breakthrough therapy designation status by the US FDA and has promising results in a phase one clinical trial.
A £600,000 grant from Cancer Research UK will fund a research study investigating the efficacy of BTK inhibiting drugs in treating mantle cell lymphoma. The trial will compare these new drugs to standard chemotherapy and aim to improve life expectancy and quality of life for patients.
Researchers at University of Cincinnati have found a Food and Drug Administration-approved therapy effective in treating older and African American patients with non-small cell lung cancer. The study suggests that gefitinib improves quality of life and outcomes for this subgroup of patients, who often face limited treatment options.
A novel combination therapy using low-dose chemotherapy with an antiangiogenic treatment, 3TSR, improved survival rates in an animal model of ovarian cancer. The treatment resulted in tumor regression, improved blood flow, and more efficient delivery of chemotherapy drugs with reduced side effects.
Researchers have developed a potent and systematic AC inhibitor, tilting the balance between pro-aging/death and pro-life chemical signals in favor of death. The compound may be used as 'chemosensitizers' to enhance anti-tumoral drug efficacy.
Researchers have developed a computational model to design fusion proteins that target cancer cells while minimizing harm to healthy cells. The model predicts the behavior of these proteins and can help identify promising candidates for drug testing.
A new review reveals that anti-cancer drugs must obtain regulatory approval, change physician prescription habits and gain patient compliance before being incorporated into daily practice.
Researchers at University of Guelph found a potential breakthrough in treating late-stage ovarian cancer by shrinking tumours and improving drug delivery. This approach may lead to novel treatment options with reduced morbidity and mortality.
Researchers at Ohio State University have discovered a promising therapy combining an oncolytic virus with doxorubicin to treat advanced or recurrent ovarian cancer. The treatment showed significant antitumor activity in animal models, increasing survival and inducing programmed cell death in cancer cells.
A recent study published in the British Journal of Surgery found that extending surgical resection after two cycles of chemotherapy may be beneficial for some pediatric patients with hepatoblastoma. The research, conducted at Children's Hospital Los Angeles, suggests a potential reduction in complications from chemotherapy.
Researchers at Paxman Coolers and the University of Huddersfield are developing new scalp cooling technology to improve hair preservation rates among cancer patients. The project aims to increase hair retention from 50% to 80%, with the goal of reducing hair loss during chemotherapy.
Research at Children's Hospital Los Angeles found that obese patients with acute lymphoblastic leukemia are more than twice as likely to have minimal residual disease, a strong predictor of long-term survival and disease recurrence. The study suggests modifying chemotherapy regimens for obese patients may improve outcomes.
A new study found that nearly two-thirds of patients treated for stage 3 colorectal cancer reported some measure of financial burden due to their treatment. The burden was greatest among patients who received chemotherapy and younger patients in low-paying jobs.
Scientists at Brigham Young University have discovered two proteins that trigger autophagy in cancer cells, offering a potential therapeutic avenue for targeted treatment. The study's unique approach led to the identification of a protein pair responsible for switching on autophagy under stress conditions.
Recent trends in cancer drug spending show a significant increase, with hospitals profiting from discounted prices through the 340B program. Researchers found that hospitals serving more affluent communities increased their profits, while patients may not receive the intended discounts.
Researchers have identified a class of chemical compounds that make cancer cells more sensitive to chemotherapeutic drugs. The compounds, referred to as T8, specifically target the protein disulfide isomerase enzyme and induce programmed cell death in rapidly dividing cancer cells.
Preliminary data from a phase III trial suggest nivolumab achieves better response rates and longer response durations than standard chemotherapy in patients with unresectable metastatic melanoma. The drug has a lower toxicity profile compared to chemotherapy, promoting a sustained immune response.
The IMPRESS trial found that continued gefitinib therapy after resistance development in lung cancer did not improve progression-free survival. Chemotherapy alone remains the standard treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Adding cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival for patients with relapsed or metastatic cervical cancer. The study, published in Annals of Oncology, shows greater tumour shrinkage and increased median progression-free survival compared to chemotherapy alone.
The CLEOPATRA study demonstrated a significant survival benefit of 15.7 months with the combination therapy, outperforming previous studies. The long-term safety profile and cardiac safety were also maintained.
A Korean study showed that patients with low levels of thymidylate synthase in their lung tumors experienced greater benefits from treatment with pemetrexed and cisplatin. The enzyme's expression level can also serve as a prognostic biomarker for overall survival.
A phase III trial showed that Rolapitant significantly reduced nausea and vomiting in patients receiving cisplatin-based chemotherapy. The study found that 72.7% of patients experienced complete response, with improved quality of life outcomes.
Children exposed to chemotherapy or radiotherapy in utero suffer no negative impacts on mental or cardiac development, according to international studies presented at ESMO 2014. These findings confirm that chemotherapy and radiotherapy during pregnancy do not endanger the fetus and its subsequent development.
Researchers at St. Jude Children's Research Hospital found that adjusting treatment based on early response to chemotherapy significantly boosts the survival of young patients with a poor-prognosis leukemia subtype associated with the Philadelphia chromosome-like acute lymphoblastic leukemia. The study included 344 children and adolesc...
A study from the University of Pennsylvania found that combining exercise with chemotherapy shrunk tumors more than chemotherapy alone in a mouse model of melanoma. Exercise increased blood flow to the tumor, bringing more of the drug into the bloodstream, and may help reduce side effects.
A study published in the Journal of Clinical Pathology suggests that adding a wild berry extract to chemotherapy cycles may improve treatment outcomes for pancreatic cancer. The researchers found that the extract induced cell death and boosted the effectiveness of the conventional drug gemcitabine.
A study found that combining chemotherapy and stereotactic ablative radiation (SABR) may be an effective treatment option for patients with locally advanced pancreatic cancer. After undergoing this treatment, nearly 90% of patients were able to undergo surgery, resulting in a high success rate.
A combination of chemotherapy drugs cisplatin and pemetrexed improved survival rates and response to advanced cervical cancer by 31% compared to standard alternative, while being less toxic to patients. Adding bevacizumab further increased patient survival, suggesting the cocktail may offer further benefits.
Pitt researchers identify natural TH17 cells as a key player in preventing oral thrush, a common infection among HIV patients and those with impaired immune systems. These innate immune cells produce IL-17 to fight Candida albicans, a fungus that causes painful white lesions.
A new antifungal, isavuconazole, has been shown to be as effective as an existing drug, voriconazole, in treating invasive mold disease in cancer patients. Isavuconazole had significantly fewer drug-related adverse events than voriconazole, particularly in the eye, skin, and liver.
A new blood test developed by researchers at the University of Manchester and The Christie NHS Foundation Trust may soon be used to tailor treatment for ovarian cancer patients. The test predicts patient response to targeted therapies such as bevacizumab, allowing for personalized treatment plans while sparing those unlikely to benefit.
Researchers found BIM deletion independently predicts overall and progression-free survival in advanced NSCLC patients, particularly in those treated with EGFR TKIs or chemotherapy. The study suggests considering BIM deletion as a clinical trial stratification factor for Asian NSCLC patients.
Researchers at Norwegian University of Science and Technology discovered that eliminating nerve signals sent to cancer stem cells can suppress gastric tumor growth. Botox, commonly used for beauty treatments, was found to be highly effective in treating stomach cancer.
A study in The Journal of Molecular Diagnostics found a combination of nucleic acid sequence-based amplification and real-time quantitative PCR detects aspergillosis with 100% accuracy. This diagnostic test has the potential to improve patient outcomes by providing early detection of this potentially deadly fungus.
Scientists have successfully tested a new treatment for aggressive brain cancer, using tiny gold nanoparticles to kill tumour cells. The treatment combines chemotherapy with radiotherapy, targeting cancer cells directly and enhancing the impact of conventional treatments.